Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Hosted on MSN4d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...
Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...
TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... Program Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation ...
Regeneron also resubmitted the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma, to the FDA. The EC also approved Kevzara (sarilumab) for the ...
Its incidence varies by bispecific antibodies and disease subtype ... Bristol Myers Squibb (BMS), Janssen, Takeda, AbbVie, Regeneron, and Sanofi; and advisory board membership with Pfizer and Sanofi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback